| NCT ID | NCT05262907 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | Congenital Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-07-08 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-07-08 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will validate a coordinate-based 3-dimensional echocardiographic technique for the assessment of cardiac size and function in children and young adults with functional single ventricles.
Eligibility Criteria
Inclusion Criteria: * All patients with functional single ventricles will be included, regardless of age or surgical palliation stage, who have had or are having a clinically ordered transthoracic echocardiogram and/or cardiac MRI. Exclusion Criteria: * Patients with congenital heart disease other than functional single ventricles, patients with single ventricle physiology (but not single ventricle anatomy) following a biventricular conversion pathway, or patients unable to understand or consent in English will be excluded.
Contact & Investigator
Piers Barker, MD
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT05262907 clinical trial?
This trial is open to participants of all sexes, studying Congenital Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05262907 currently recruiting?
Yes, NCT05262907 is actively recruiting participants. Contact the research team at joan.wilson@duke.edu for enrollment information.
Where is the NCT05262907 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT05262907 clinical trial?
NCT05262907 is sponsored by Duke University. The principal investigator is Piers Barker, MD at Duke University. The trial plans to enroll 100 participants.